Daily Brief Health Care: Manipal Health Enterprises Ltd, Apnimed, Agenus Inc, Butterfly Network Inc, Coherus Biosciences, Seer , Aadi Bioscience and more

• Manipal Health Enterprises  (MHEL) is looking to raise up to US$960m in its upcoming India IPO.
• MHEL operates a pan‑India network of multispecialty hospitals delivering a range of care services, from outpatient services to complex tertiary and quaternary interventions.
• We have looked at the past performance in our previous note. In this note, we talk about the RHP updates and valuations.

• Apnimed is expected to list on the Nasdaq under the ticker APMD, offering 10.0 million shares at a price range of $14.00 to $16.00 per share, targeting approximately $150 million in gross proceeds.
• The company is a late-stage biopharmaceutical developer focused on AD109, an investigational oral therapy for obstructive sleep apnea (OSA), a large and underserved market traditionally treated with CPAP devices.
• The company recently received FDA acceptance of its New Drug Application (NDA) for AD109, with a PDUFA action date of February 28, 2027, representing a significant regulatory milestone.

• Apnimed (NASDAQ: APMD) is seeking to raise $150 million through the sale of 10.0 million shares priced between $14.00 and $16.00, implying a midpoint offering price of $15.00 per share.
• At the midpoint, the company would command an estimated fully diluted market capitalization of approximately $570 million based on approximately 38.0 million shares outstanding after the offering. 
• The IPO is being led by BofA Securities, Evercore ISI, Cantor, and LifeSci Capital, with trading expected to begin Friday, July 31.

• Agenus is a clinical-stage immuno-oncology company with a focused pipeline centered on its lead combination therapy, botensilimab (BOT) and balstilimab (BAL), targeting difficult-to-treat cancers.
• The company’s value is heavily dependent on the clinical and regulatory success of the BOT/BAL program, with a pivotal Phase 3 trial in metastatic colorectal cancer underway.
• Recent strategic partnerships and a sharpened focus on the BOT/BAL program have improved the company’s financial position, though it remains a high-risk, high-reward investment proposition typical of the biotechnology sector.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Butterfly Network is a disruptive force in the medical imaging market with its proprietary ‘Ultrasound-on-Chip™’ technology, which enables a portable, single-probe, whole-body ultrasound system at a lower cost than traditional equipment.
• The company is in a high-growth phase, evidenced by strong revenue increases and a strategic focus on expanding its software and AI ecosystem; however, it has a history of significant net losses and cash burn, with profitability remaining a future goal.
• Facing a competitive landscape of established medical device giants and other innovators, Butterfly’s success hinges on its ability to drive widespread adoption, scale its enterprise-level software solutions, and effectively manage its path to profitability.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Coherus is undergoing a significant strategic transformation, divesting its biosimilar portfolio to become a pure-play, revenue-generating oncology company focused on innovative immuno-oncology (I-O) therapies.
• The company’s future is now centered on its sole commercial product, LOQTORZI® (toripalimab-tpzi), a next-generation PD-1 inhibitor, and its mid-stage I-O pipeline candidates, casdozokitug and tagmokitug.
• Recent divestitures of its biosimilar assets, including UDENYCA®, have significantly strengthened the balance sheet, providing capital to pay down debt and fund the focused oncology strategy through key clinical milestones in 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• This is going to be a mostly Claude written article as I am extremely busy today, but I think this needs to get out immediately and this is too long for a note.
• Also not a large position for me, but it is about to have a huge inflection point (up or down).
• Forgive any errors as I am literally writing this over lunch and feel free to correct me in the comments.

• Aadi Bioscience is a commercial-stage biopharmaceutical company centered on its sole approved product, FYARRO (nab-sirolimus), for a rare cancer, making it highly dependent on this single asset.
• The company’s primary value driver is the potential label expansion of FYARRO into other cancers with mTOR pathway alterations, though the pivotal PRECISION1 trial for a tumor-agnostic indication was halted in August 2024 due to lack of efficacy.
• Aadi faces significant financial pressure, characterized by a high cash burn rate, consistent net losses, and a recent strategic pivot involving the sale of FYARRO and a shift to preclinical antibody-drug conjugates (ADCs).

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.